Hanmi Pharmaceutical Nears Korean Launch for Obesity Drug EPPE After Five-Year Detour
Licensed out to French pharmaceutical giant Sanofi in 2015 and returned five years later, Hanmi Pharmaceutical’s obesity drug candidate "EPPE" has...
Search results for "GLP-1 obesity treatment"
Hanmi Licenses Muscle-Preserving Obesity Drug Candidate to Genentech in $2.3 Billion Deal
Hanmi Pharmaceutical has entered into an exclusive global licensing agreement with Genentech, a member of the Roche Group, for its next-generation...
Losing Weight Fast on Wegovy or Mounjaro? How High-Protein Foods Prevent Rebound
Popular anti-obesity injections like Wegovy and Mounjaro reduce appetite and prolong feelings of fullness.
Eli Lilly Licensing Deal Surge: Hanmi Pharmaceutical’s Q2 Operating Profit Jumps 117%
Hanmi Pharmaceutical posted a sharp profit surge in the second quarter of this year, buoyed by a major...
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven
Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.
Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market
The glucagon-like peptide-1 (GLP-1) obesity treatment market, long dominated by subcutaneous injections, is rapidly...
Maximizing Weight Loss vs. Protecting the Heart: The Paradox of Modern Anti-Obesity Drugs
As global demand for anti-obesity medications surges, a fierce pharmaceutical race is underway to develop...
Considering Wegovy for Weight Loss? South Korea's Drug Safety Ministry Warns It Is Not for Everyone
South Korea’s Ministry of Food and Drug Safety issued a strong warning on July 8 against the misuse and abuse of GLP-1...
The GLP-1 Paradox: Wegovy and Mounjaro Patients Shed Weight, but Walk Less
"First I’ll lose the weight, and then I’ll start exercising." It is a thought shared by almost anyone starting highly...
HK inno.N’s Obesity Drug Candidate Outperforms Wegovy in Head-to-Head Phase 2 Trial
HK inno.N announced on June 9 that its obesity drug candidate, ecnoglutide, demonstrated superior weight-loss efficacy...